Hereditary angioedema: 24 years of experience in a Portuguese reference center

Transitioning Patients From Second- to First-Line Prophylaxis in Hereditary Angioedema

“…9 However, despite the recommendations for first-line targeted treatments, a significant number of existing patients with HAE across Europe are still being prescribed AAs. [4][5][6][7] Gurugama and Launay agree that this is, at least partly, because AAs are less costly, and clinicians and patients are very familiar with these medicines. Gurugama said: "We have a cohort of more than 100 patients at our tertiary clinic, and many of them have been taking AAs for 20-30 years."…”

“…1 However, a significant proportion of patients throughout Europe and the USA are still prescribed AAs, which are not recommended as first-line prophylaxis in the guidelines. 1,[4][5][6][7][8] To find out why this is the case, and to understand what can be done to ensure more patients can access first-line prophylactics, EMJ interviewed David Launay, Department of Internal Medicine and Immunology, Hospital Centre, University of Lille, France; and Padmalal Gurugama, Clinical Immunology and Allergy, Cambridge University Hospitals NHS Foundation Trust, UK, who are both experts managing patients with HAE in specialist centres.…”